Authors
Latest:
Assessing Clinical Relevancy of Visual Biomarkers in Alzheimer Disease: Alfredo A. Sadun, MD, PhDThe chief of ophthalmology at the Doheny Eye Institute discussed decades of research uncovering how Alzheimer can impact visual function and how retinal imaging may advance diagnosis. [WATCH TIME: 13 minutes]
Latest:
Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MDThe executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]
Latest:
Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhDThe Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]
Latest:
B Cells as a Treatment Target in Myasthenia GravisAli Habib, MD, and Arjun Seth, MD, discuss how B-cell–targeted therapies represent a promising upstream treatment approach for myasthenia gravis that could provide more sustained efficacy compared with current downstream treatments like complement inhibitors and FcRn antagonists, with CD19-targeting agents like inebilizumab showing particular promise in clinical trials for both acetylcholine receptor and MuSK antibody subtypes.
Latest:
Pediatric AES Insights: Addressing Health Disparities and Advancing Neonatal Epilepsy CarePediatric epilepsy specialists Adam Numis, MD, and Laura Kirkpatrick, MD, highlighted efforts to standardize data collection for pediatric epilepsy health equity and improve neonatal epilepsy outcomes.
Latest:
Engaging the Clinical and Patient DMD Community at the 2025 FUTURES Conference: Heather Medlin, MSWThe associate vice president of community outreach at CureDuchenne talked about events like the 2025 FUTURES National Conference that aim to bring individuals from the Duchenne community together. [WATCH TIME: 6 minutes]
Latest:
Next Steps for ATA188, Research Related to EBV and Multiple Sclerosis: AJ Joshi, MDThe chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]
Latest:
Final Analyses Highlight Efficacy of THC-CBD Combination Therapy for Acute MigraineNathaniel M. Schuster, MD, associate clinic director at the UC San Diego, talked about findings from a study of vaporized cannabis in treating patients with acute migraine presented at AHS 2025.
Latest:
Lifting Barriers to Equitable Care in EpilepsyFour neurologists treating patients with epilepsy share their experience in and out of the clinic tackling issues of access for their patients.
Latest:
The Changing Landscape of Preventative Migraine TreatmentsA panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.
Latest:
AUPN Leadership Minute Episode 9: Engaging Medical Students in Neurology – Part 2Episode 9 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the Veterans Health Administration; and Douglas J. Gelb, MD, PhD, of the University of Michigan [WATCH TIME: 5 minutes]
Latest:
The Evolving Diagnostic Criteria for Multiple SclerosisJoin Ahmed Obeidat, MD, PhD; Hesham Abboud, MD, PhD; and Rana K. Zabad, MD, FAAN, for perspectives on how the diagnostic criteria for multiple sclerosis have evolved over time.
Latest:
Building a Greater Understanding for NMOSD Treatments, Neurodegeneration: John Chen, MD, PhDThe neuroophtalmologist at Mayo Clinic detailed improvements in prescribing methods for NMOSD treatments and the conversations surrounding reversing neurodegeneration. [WATCH TIME: 3 minutes]
Latest:
The Unresolved Bottleneck of Accessing Care for Mental Health in MS: Bernd C. Kieseier, MDThe global program head of the development unit for neuroscience at Novartis talked about the evolving landscape of mental health care for multiple sclerosis including the accessibility barrier that remains for patients in many regions. [WATCH TIME: 4 minutes]
Latest:
Preparing for the Future of Rare Disease Treatment: Robert Califf, MDThe former FDA commissioner discussed the collaborative power of the neuromuscular community and the challenges of implementing emerging therapies in a rapidly evolving care landscape. [WATCH TIME: 4 minutes]
Latest:
Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank GleesonThe president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]
Latest:
Assessing the Felix NeuralAI Wristband for Essential Tremor Management: Zhen Zhang, PhD, & Rajesh Pahwa, MDThe president at Fasikl and the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center talked about results from a pilot study assessing the Felix Neural AI wristband in patients with essential tremor. [WATCH TIME: 4 minutes]
Latest:
Insights From Comprehensive Research on Epilepsy and Cognitive Decline: Ifrah Zawar, MDThe assistant professor of neurology at the University of Virginia talked about findings from a comprehensive study on epilepsy and mild cognitive impairment, which was recently presented at AES 2023. [WATCH TIME: 5 minutes]
Latest:
Hormonal Influences on Sleep Disorders in Women: Suzanne Bertisch, MDThe chair of the Women’s Sleep Health Task Force at the American Academy of Sleep Medicine talked about how hormonal changes across a woman’s lifespan influence the prevalence of sleep disorders. [WATCH TIME: 4 minutes]
Latest:
CMSC Live: 2025 Annual Meeting Day 1Host Jeffrey Wilken, PhD, chats with Marie Namey, APRN, MSCN, about the first day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Latest:
Air Pollution’s Impact on Cognitive Decline and the Neurotoxicity of Particulate Matter: Masashi Kitazawa, PhDThe associate professor of environmental and occupational Health at the University of California, Irvine, talked about the impact of concentrated particulate matter or air pollution on cognitive function in animal models. [WATCH TIME: 5 minutes]
Latest:
Preventing Secondary Stroke: Practical Application of Updated GuidelinesExperts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.
Latest:
How Vidofludimus Calcium Addresses Unmet Treatment Needs in Multiple Sclerosis: Andreas Muehler, MD, MBAThe chief medical officer at Immunic provided clinical insight on the dual mechanism of action of vidofludimus calcium, and how its positioned as a treatment option across all MS subtypes. [WATCH TIME: 3 minutes]
Latest:
Bridging the Gaps in Duchenne Muscular Dystrophy: Multidisciplinary Approaches for Better OutcomesDuchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
Latest:
Advancing Clinical Trials and Treatment Strategies for Charcot-Marie-Tooth Disease: Joshua Burns, PhDThe clinical researcher at St. Jude Children's Research Hospital discussed the evolving treatment landscape for Charcot-Marie-Tooth disease, which will be featured in a session at the 2025 MDA Conference. [WATCH TIME: 7 minutes]
Latest:
Physical Therapy, Optimizing Function in Neuromuscular Diseases: Megan Iammarino, PT, DPTThe research physical therapist at Nationwide Children’s Hospital talked about the role of physical therapy in the changing landscape of care with neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Latest:
Bruton Tyrosine Kinase Inhibitors: A New Hope for the Management of Progression in MS?Several therapies are progressing through the development pipeline and have shown promising data, setting up the multiple sclerosis treatment toolbox for possible expansion in coming years.
Latest:
Characterizing Real-World Outcomes With Eptinezumab in Migraine: Zubair Ahmed, MDThe neurologist from Cleveland Clinic discussed the importance of studying real-world outcomes in patients with migraine using CGRPs such as eptinezumab.
Latest:
The Future of Multiple Sclerosis TreatmentAhmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, share their hopes about the evolution of future mutiple sclerosis care and express their gratitude for the next generation of neurologists.
Latest:
The Paradigm Shift in Therapeutic Intervention for ALS: Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMSThe Bushell Chair of Neurology at the University of Sydney offered his perspective on phase 2 data of CNM-Au8 in amyotrophic lateral sclerosis and spoke to the advances that the field has made in recent years. [WATCH TIME: 3 minutes]
